Post by
SundayMovies on Dec 05, 2022 9:55am
Accelerated Approval after Bracelet-1
I think it is now okay to expect stelar results from Bracelet-1 (confirmation of IND-213) based on pancreatic and upcoming Adlai results (on Dec 7th ...)
The stock should be trading near full valuation soon (15 USD)
Comment by
Lesalpes29 on Dec 05, 2022 10:20am
Speculation of course. We don't know yet what will be posted on Dec 7th. Hope for good results and a pop of the SP.
Comment by
Lesalpes29 on Dec 05, 2022 10:45am
By the way I love your guess!
Comment by
SundayMovies on Dec 05, 2022 11:54am
The market is comatose because of the inflation environment. Not even sure why ONCY is trading so low. In a normal market, things would be at 5 or 6 USD already.
Comment by
fox7mf on Dec 05, 2022 12:29pm
SundayMovies guesses are indeed educated, and we should continue to assume that the news this week will be stellar. Onc aren't showing up to release ho-hum data to the scientific community, they're featured presenters of embargoed news/data, Smacks of importance, and we will soon see. Good luck all!!!
Comment by
Noteable on Dec 05, 2022 1:03pm
ONCY should be acquired well before then.
Comment by
SundayMovies on Dec 05, 2022 1:21pm
It possible that ONCY gets acquired before but from an unknown third party. More likely scenario is hedges funds will acquired/accumulated less than 10% and wait it out. In any case, recent developments is fuelling many positive scenarios for the stock!!!
Comment by
fox7mf on Dec 05, 2022 1:39pm
Unknown third party? Are you talking a lowball, hostile takeover? Based on Goblet & Aware results, I think Roche will make an offer, if they haven't already, and PFE will be playing catch up. The 90 day exclusivity has been disrupted by the recent results. We may have a bidding war
Comment by
fox7mf on Dec 05, 2022 1:52pm
Indeed an interesting scenario for interesting times at ONC. I have no idea what kind of lowball offer may or may not come our way, but I think Roche will strike first.
Comment by
Noteable on Dec 05, 2022 2:16pm
ONCY is working its way towards the approval of pelareorep in the treatment of HR+ (positive) / HER2- (negative) metastatic breast cancer while Enhertu is approved for HR+/- (positive/negative) / HER2 (low) metastatic breast cancer - a significant difference between the two types of mBC.
Comment by
SundayMovies on Dec 05, 2022 2:22pm
okay would you not want to own both market and dominate? That's why I think AstraZeneca will come into the play and offer 7 billions. This is 70 times the current share price. This market is a joke. I bough more today from clueless shareholders. I even posted everything to inform anyone and share price is still pathetic...
Comment by
TMAZZ21 on Dec 05, 2022 2:26pm
Wow that would be amazing, I have never seen a stock go from $2 to $140 overnight or even or the week! If you have some recent examples where a stock has gone 50 x the current trading price, I would love to see it! Regardless I so hope your right! :)
Comment by
SundayMovies on Dec 05, 2022 2:34pm
That's my example.https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-the-us-for-her2-low-mbc.html Just breast Her whatever is worth 6.9 Billions. I haven't even counted pancreatic etc. So, as soon as the results are in and they checked by nerds. Well, the sky seems to be very high. Not understanding why this stock is not trading in the 500M...
Comment by
Buckhenry on Dec 05, 2022 2:33pm
you folks need to reel this back in... you have too many visions of sugar plums dancing in your head. lets just wait for official information
Comment by
fox7mf on Dec 05, 2022 2:46pm
Again, very interesting. AstraZeneca entering the fray in such a scenario would be mind blowing. I'd sign off on $7b usd. I love your definition of 'lowball' lol.